eletriptan / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 7 Diseases   0 Trials   0 Trials   179 News 


12»
  • ||||||||||  eletriptan / Generic mfg.
    Advancing migraine therapy with novel mucoadhesive eletriptan formulations (MCP Hall A) -  Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_12965;    
    Additionally, analytical methods for eletriptan estimation using UV-visible spectroscopy and HPLC with UV detection were developed and validated. Results demonstrated the potential of mucoadhesive formulations to enhance drug absorption and efficacy, offering a promising avenue for improving migraine therapy outcomes.
  • ||||||||||  Ganaton (itopride) / Abbott
    PK/PD data, Preclinical, Journal:  Statistically Optimized Polymeric Buccal Films of Eletriptan Hydrobromide and Itopride Hydrochloride: An In Vivo Pharmacokinetic Study. (Pubmed Central) -  Nov 25, 2023   
    The drug was found to rapidly permeate across the buccal mucosa, leading to increased bioavailability of the drug: C of 130 and 119 ng/mL of ITHC and EHBR, respectively, as compared to 96 (ITHC) and 90 ng/mL (EHBR) of oral solution. The conclusion can be drawn that possible reasons for the enhanced bioavailability could be the increased surface area in the form of buccal films, its rapid disintegration, and faster dissolution, which led toward the rapid absorption of the drug into the blood stream.
  • ||||||||||  ONZETRA Xsail (sumatriptan intranasal) / Otsuka, Tosymra (intranasal sumatriptan) / Sawai Pharma, Neurelis, ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
    Journal:  Comparison table: Triptans. (Pubmed Central) -  Jun 6, 2023   
    2010; 11(1):5-12. No abstract available
  • ||||||||||  Journal:  Drugs for migraine. (Pubmed Central) -  Jun 6, 2023   
    No abstract available No abstract available
  • ||||||||||  Review, Journal:  The Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric Migraine: A Systematic Review. (Pubmed Central) -  May 20, 2023   
    We found that rizatriptan (good tolerability profile with a dose of 5 mg) and sumatriptan (oral administration) had higher efficiency as compared to other triptans. Regardless of type or dose, all triptans are generally well tolerated by patients, but a few adverse effects such as light-headedness (sumatriptan), nasopharyngitis, and, muscular spasms (sumatriptan/ naproxen), somnolence, and dry mouth (rizatriptan), and dizziness (zolmitriptan group) were reported with the triptans.
  • ||||||||||  eletriptan / Generic mfg.
    Journal:  Oral transmucosal delivery of Eletriptan for neurological diseases. (Pubmed Central) -  Oct 21, 2022   
    Moreover, we show that the chemical permeation enhancer DMSO can be used to enhance the drug permeation significantly (i.e., 12 to 36-fold increase). Taken together, this study presents important findings on transmucosal delivery of eletriptan via the oral cavity and paves the way for clinical investigations for a fast and safe migraine treatment.
  • ||||||||||  eletriptan / Generic mfg.
    Journal:  Chitosan/guar gum-based thermoreversible hydrogels loaded with pullulan nanoparticles for enhanced nose-to-brain drug delivery. (Pubmed Central) -  Aug 5, 2022   
    In this study, poloxamers PF-127/PF-68 grafted chitosan HCl-co-guar gum-based thermoresponsive hydrogel loaded with eletriptan hydrobromide laden pullulan nanoparticles was synthesized and subjected to dynamic light scattering, Fourier transform infrared spectroscopy, thermal analysis, x-ray diffraction, scanning electron microscopy, stability studies, mucoadhesive strength and time, gel strength, cloud point assessment, rheological assessment, ex-vivo permeation, cell viability assay, histology studies, and in-vivo Pharmacokinetics studies, etc. It is quite evident that CSG-EH-NPs T-Hgel has an enhanced sustained release drug profile where approximately 86 % and 84 % of drug released in phosphate buffer saline and simulated nasal fluid respectively throughout 48 h compared to EH-NPs where 99.44 % and 97.53 % of the drug was released in PBS and SNF for 8 h. In-vivo PKa parameters i.e., mean residence time (MRT) of 11.9 ± 0.83 compared to EH-NPs MRT of 10.2 ± 0.92 and area under the curve (AUC) of 42,540.5 ± 5314.14 comparing to AUC of EH-NPs 38,026 ± 6343.1 also establish the superiority of CSG-EH-NPs T-Hgel.
  • ||||||||||  sumatriptan succinate / Generic mfg.
    Clinical, Journal:  Twenty-five years of triptans - a nationwide population study. (Pubmed Central) -  Dec 16, 2021   
    In a cohort with access to free clinical consultations and low medication costs, we observed low rates of triptan adherence, likely due to disappointing efficacy and/or unpleasant side effects rather than economic considerations. Triptan success continues to be hindered by poor implementation of clinical guidelines and high rates of treatment discontinuance.
  • ||||||||||  Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
    [VIRTUAL] LasmiGepant: A case report of simultaneous administration of lasmiditan and rimegepant () -  Jun 4, 2021 - Abstract #AHS2021AHS_366;    
    New treatments target specific migraine pathways with potentially less impact on unrelated neural activity or organ systems. As a result, no single, currently available treatment addresses the breadth of the pathophysiological cascade of migraine, nor demonstrates consistent efficacy across all patients.
  • ||||||||||  sumatriptan succinate / Generic mfg.
    [VIRTUAL] Pharmacokinetic and pharmacodynamic variability of triptans. A review and some clinical implications () -  Jun 4, 2021 - Abstract #AHS2021AHS_318;    
    In addition to the pharmacokinetic variability, probably mainly due to genetic differences in metabolizing enzymes, potential explanations for the total variability of triptans could be genetic variations in transporters mediating blood-cell transport, and brain drug disposition where uptake and efflux transporters possibly play a role. Finally, variations in target function, pharmacodynamics, most likely play a large role.
  • ||||||||||  duloxetine / Generic mfg.
    [VIRTUAL] COVID-19 related headache exquisite response to therapy () -  Jun 4, 2021 - Abstract #AHS2021AHS_184;    
    For patients with chronic migraine with superimposed head pain with mixed features related to COVID-19, Parafon Forte burst (500 mg TID x 5 days) may be a feasible and effective treatment modality since options as NSAIDS, triptans or steroids may be contradicted or ineffective. As the pandemic further evolves, headache being both a presenting symptom of COVID-19 and residual manifestation, further research into more effective and safe treatment for these patients will be necessary.
  • ||||||||||  sumatriptan oral spray (SUD-001) / Suda, Strides Pharma Science
    [VIRTUAL] Estimated migraine acute-therapy savings, from MMD reduction achieved with preventive treatment () -  Mar 18, 2021 - Abstract #AAN2021AAN_1144;    
    Non-oral and/or branded triptans accounted for ~5% (Medicaid: 3.1% subcutaneous SS and 1.5% nasal sumatriptan; Medicare: 2.0% branded oral eletriptan and 1.6% nasal sumatriptan)... In migraineurs with high MMDs, reduced use of non-oral/branded triptans resulting from preventive treatment may yield large savings.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie
    Journal:  Drugs for Migraine. (Pubmed Central) -  Jan 23, 2021   
    These findings suggest that eletriptan is non-cytotoxic but potentially weakly genotoxic at higher concentrations (10 and 25 µg/ml). No abstract available
  • ||||||||||  eletriptan / Generic mfg.
    Preclinical, Journal:  Drug-responsive autism phenotypes in the 16p11.2 deletion mouse model: a central role for gene-environment interactions. (Pubmed Central) -  Dec 16, 2020   
    The ability of the excitation/inhibition modulator N-acetyl cysteine (NAC) and the 5-HT receptor agonist eletriptan to normalise the behavioural deficits observed was tested...The data suggest that 16p11.2 DEL mice show an autism-relevant phenotype that becomes overt after an acute stressor, emphasising the importance of gene-environmental interactions in phenotypic analysis. Further, they add to an emerging view that NAC, or 5-HT receptor agonist treatment, may be a promising strategy for further investigation as a future treatment.
  • ||||||||||  [VIRTUAL] Treating Red Ear Syndrome with Oxygen () -  Jul 15, 2020 - Abstract #AHS2020AHS_282;    
    We hypothesize that oxygen treated the underlying trigeminal autonomic cephalalgia thus effectively treating the associated red ear syndrome. More research is necessary to confirm our findings.
  • ||||||||||  eletriptan / Generic mfg., ibuprofen / Generic mfg.
    [VIRTUAL] Eletriptan (RelpaxaTm) Causing False Positive Elevations in Urinary Metanephrine () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_293;    
    Eletriptan, a second generation triptan drug, is a selective 5-hydroxytryptamine 1B/1D receptor agonist and has been shown to reduce carotid arterial blood flow, with only a small increase in arterial blood pressure at high doses. However, Eletriptan has no significant affinity or pharmacological activity at adrenergic α1, α2, or β; dopaminergic D1 or D2; muscarinic; or opioid receptors.
  • ||||||||||  Analgin (metamizole) / Sedico, eletriptan / Generic mfg., zolmitriptan / Generic mfg.
    [VIRTUAL] Dialysis headache: 4 cases of a tertiary headache centre (Room: Screen B4) -  Apr 9, 2020 - Abstract #EAN2020EAN_1945;    
    There is not a specific pattern for DH, besides its temporal profile and its relation to HD. Response to triptans in one suggests a migraine-type pathophysiology.
  • ||||||||||  Ubrelvy (ubrogepant) / Allergan, Reyvow (lasmiditan) / Eli Lilly, rimegepant (BHV-3000) / Portage
    [VIRTUAL] LONG-TERM COST-EFFECTIVENESS OF LASMIDITAN, UBROGEPANT AND RIMEGEPANT FOR TREATMENT OF ACUTE MIGRAINE () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_341;    
    Lasmiditan, rimegepant, and ubrogepant may provide an important therapeutic alternative to current treatments for acute migraine in patients who cannot tolerate or have contraindications to triptans. Pricing of these drugs will determine whether they are cost effective at commonly accepted thresholds.